Dr. Hughes on Switching From Imatinib to Nilotinib in CML

Video

Timothy P. Hughes, MD, MBBS, explains the two-year follow-up results of the ENESTcmr trial analyzing the switch to nilotinib after at least 2 years on imatinib in patients with chronic phase chronic myeloid leukemia.

Timothy P. Hughes, MD, MBBS, Royal Adelaide Hospital, Adelaide, Australia, explains the two-year follow-up results of the ENESTcmr trial analyzing the switch to nilotinib after at least 2 years on imatinib in patients with chronic phase chronic myeloid leukemia (CML-CP).

The trial analyzed Philadelphia chromosome-positive (Ph+) CML-CP patients on imatinib who had achieved complete cytogenetic responses but failed to achieve BCR-ABL polymerase chain reaction negativity after at least two years of therapy. The control arm of the study remained on imatinib at 400 mg/day or 600 mg/day while the experimental arm began receiving 400 mg nilotinib twice daily.

The two-year analysis found that substantially more patients achieved deep molecular responses in the nilotinib arm (32.7% on nilotinib vs 16.5% on imatinib; P =.005). Among patients who had not yet achieved a major molecular response did so at a much higher rate after switching to nilotinib (over 85% on nilotinib arm vs about 50% on imatinib), Hughes says.

Related Videos
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD